Secretin receptor Inhibitors
1 drugsAbout Secretin receptor
The Secretin receptor (SCTR) is a G protein-coupled receptor that binds the peptide hormone secretin, regulating fluid and electrolyte balance in the digestive system.
SCTR is a druggable target with one approved drug, CHIRHOSTIM, despite the lack of genetic evidence linking it to specific diseases.
CHIRHOSTIM, a small molecule, is the only approved drug targeting SCTR, and it was first approved in 2004. CHIRHOCLIN is the sole company with an approved drug.
Top Secretin receptor Drugs
CHIRHOCLIN is the only company with an approved drug targeting the Secretin receptor.
Low competition suggests high barriers to entry or limited perceived market opportunity for SCTR-targeting drugs.
Secretin receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Secretin receptor, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for novel biologics targeting SCTR.
Secretin receptor Clinical Trials 6 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Secretin receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 2 | 2 | 0 | 0 | 100% |
| Phase 3 | 1 | 0 | 0 | 1 | - |
| Phase 4 | 2 | 1 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Secretin receptor Drug Approval Timeline (2004 - 2004)
The first and only drug targeting SCTR, CHIRHOSTIM, was approved in 2004.
The stagnant approval timeline indicates a potentially saturated market or challenges in developing new SCTR-targeting therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 5 (0 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Secretin receptor. A trial counts if an approved drug acting on Secretin receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.